Identification of distinct immunophenotypes in chronic pulmonary aspergillosis using cluster analysis

Background Whether chronic pulmonary aspergillosis (CPA) has different immunophenotypes remains unknown. Objective To identify different CPA immunophenotypes using cluster analysis. Methods We used a subject‐centred multivariate clustering approach without prior assumptions to identify CPA phenotype...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mycoses 2023-04, Vol.66 (4), p.299-303
Hauptverfasser: Sehgal, Inderpaul S., Dhooria, Sahajal, Muthu, Valliappan, Rudramurthy, Shivaprakash M., Prasad, Kuruswamy T., Chakrabarti, Arunaloke, Aggarwal, Ashutosh N., Agarwal, Ritesh
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Whether chronic pulmonary aspergillosis (CPA) has different immunophenotypes remains unknown. Objective To identify different CPA immunophenotypes using cluster analysis. Methods We used a subject‐centred multivariate clustering approach without prior assumptions to identify CPA phenotypes. We retrospectively included the data of treatment‐naïve subjects with CPA and excluded subjects with asthma and allergic bronchopulmonary aspergillosis (ABPA). We performed a scalable two‐step cluster analysis using the log‐likelihood distance measures to identify CPA phenotypes based on the blood immunological profile (total IgE, eosinophil count and Aspergillus‐specific IgE and IgG). Results We included 351 CPA subjects and found two clusters. Cluster 2 (n = 118) had significantly higher serum total IgE, peripheral blood eosinophil count, and serum A. fumigatus‐specific IgE and IgG than cluster 1 (n = 233). Cluster 2 subjects had a lower FEV1:FVC ratio on spirometry and were more likely to have a fungal ball (88 [74.6%] vs. 145 (62.2%), p = .023) on the CT thorax than cluster 1. After treatment discontinuation, cluster 2 had a longer median (interquartile range) time to relapse than cluster 1 (11.5 [7.3–27.4] vs. 4 [1.1–8.9] months, p = .005). Conclusion We identified two distinct CPA phenotypes, type‐2 dominant and non‐type‐2, with different clinical and radiological findings and treatment outcomes. Future studies should confirm our findings and investigate different treatment strategies based on CPA phenotypes.
ISSN:0933-7407
1439-0507
DOI:10.1111/myc.13553